ACP-204 for Lewy Body Dementia Psychosis

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

Recruiting Phase 2 Interventional Study
Lewy Body Dementia Psychosis
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
55 – 84
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
180 (estimated)
Sponsor
ACADIA Pharmaceuticals Inc. · Industry
Who this trial is looking for

This trial is looking for people aged 55 to 85 with Lewy Body Dementia Psychosis. Participants will take part in a 6-week study to find out if the drug ACP-204 is effective and safe.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am between 55 and 85 years old.
  • I can provide written consent or have a legal representative do so.
  • I have been diagnosed with Parkinson's disease with dementia or dementia with Lewy bodies.
  • I have psychosis in relation to my dementia.

You may not be able to join if

  • I am in hospice care or bedridden.
  • I have psychotic symptoms due to substance abuse or other psychiatric conditions.
  • I am actively suicidal.
  • I have a serious ongoing medical condition that affects my ability to participate.
  • I have other significant brain issues affecting my dementia.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Male or female ≥55 years to \<85 years of age at the Screening visit living in the community or, if permitted by local regulations, in an institutionalized setting * Can provide written informed consent. If the subject is deemed not competent to provide informed consent, the f…
Contacts

Kristin Kidd

434-841-3162

Kristin.kidd@acadia-pharm.com

CONTACT

Becky Howell

848-702-1886

bhowell@acadia-pharm.com

CONTACT